Related Experiment Videos
Leishmaniasis: current status of vaccine development
1Infection and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, The Royal Melbourne Hospital, Parkville 3050, Australia. handman@wehi.edu.au
Clinical Microbiology Reviews
|April 9, 2001
Summary
Developing effective vaccines against leishmaniasis, a widespread parasitic disease, is crucial due to the lack of current vaccines. Research is exploring novel vaccine strategies including genetic modifications and DNA-based approaches to combat this global health threat.
Area of Science:
- * Parasitology and Tropical Medicine: Focuses on Leishmania, an intracellular protozoan parasite.
- * Immunology: Investigates T helper type 1 immune responses for pathogen elimination.
Background:
- * Leishmaniasis presents a spectrum of diseases, from skin lesions to fatal visceral forms.
- * Affects 2 million people annually, with 1/10 of the global population at risk.
- * Current control relies on chemotherapy and vector control; no vaccines are available.
Observation:
- * A significant vaccine development program is underway, initially targeting cutaneous leishmaniasis.
- * Studies are evaluating live attenuated vaccines, recombinant antigens, and DNA-based vaccines.
- * Research includes novel adjuvants and delivery systems to elicit protective immune responses.
Findings:
- * Ongoing research explores genetically modified live attenuated vaccines and DNA encoding recombinant antigens.
- * Focus on optimizing adjuvants and delivery systems to induce T helper type 1 immunity.
- * Genomic sequencing of humans and Leishmania will enable identification of new vaccine targets.
Implications:
- * Potential for new vaccine candidates targeting parasite virulence factors.
- * Host susceptibility gene mapping may allow targeted vaccination strategies.
- * Advancements promise improved control measures against widespread leishmaniasis.